NASDAQ:DOVA - Dova Pharmaceuticals Stock Price, Forecast & News

Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA."

Dova Pharmaceuticals Inc (NASDAQ:DOVA) announced its earnings results on Tuesday, August, 6th. The company reported ($0.60) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.57) by $0.03. The firm earned $3.52 million during the quarter, compared to analysts' expectations of $5.63 million. Dova Pharmaceuticals had a negative net margin of 544.09% and a negative return on equity of 101.60%. View Dova Pharmaceuticals' Earnings History.

6 analysts have issued 1 year target prices for Dova Pharmaceuticals' stock. Their forecasts range from $15.00 to $30.00. On average, they expect Dova Pharmaceuticals' stock price to reach $26.42 in the next twelve months. This suggests that the stock has a possible downside of 5.8%. View Analyst Price Targets for Dova Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dova Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Dova Pharmaceuticals.

Media coverage about DOVA stock has trended extremely positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Dova Pharmaceuticals earned a coverage optimism score of 4.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Dova Pharmaceuticals.

Dova Pharmaceuticals saw a drop in short interest during the month of November. As of November 15th, there was short interest totalling 572,700 shares, a drop of 51.9% from the October 31st total of 1,190,000 shares. Based on an average daily volume of 587,400 shares, the short-interest ratio is presently 1.0 days. Approximately 4.4% of the shares of the stock are sold short. View Dova Pharmaceuticals' Current Options Chain.

Some companies that are related to Dova Pharmaceuticals include HUTCHISON CHINA/S (HCM), GW Pharmaceuticals PLC- (GWPH), Myokardia (MYOK), Genmab A/S (GMAB), PTC Therapeutics (PTCT), Uniqure (QURE), Biohaven Pharmaceutical (BHVN), Emergent Biosolutions (EBS), Deciphera Pharmaceuticals (DCPH), Amicus Therapeutics (FOLD), Ultragenyx Pharmaceutical (RARE), Agios Pharmaceuticals (AGIO), Zai Lab (ZLAB), Arena Pharmaceuticals (ARNA) and Xencor (XNCR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dova Pharmaceuticals investors own include Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Sasol (SSL), Aldeyra Therapeutics (ALDX), Fate Therapeutics (FATE), Heron Therapeutics (HRTX), TESARO (TSRO), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX) and Allena Pharmaceuticals (ALNA).

(DOVA) raised $66 million in an IPO on Thursday, June 29th 2017. The company issued 4,100,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Dova Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include GW&K Investment Management LLC (1.15%), State Street Corp (0.66%), Gabelli Funds LLC (0.26%), Millennium Management LLC (0.18%), GABELLI & Co INVESTMENT ADVISERS INC. (0.11%) and Virtu Financial LLC (0.07%). Company insiders that own Dova Pharmaceuticals stock include Alex Sapir, David Zaccardelli, Jason Hoitt, Kevin Laliberte, Lee F Md Phd Allen, Life Sciences Maste Perceptive, Mark W Hahn, Paul B Manning, Roger Jeffs and Steven M Goldman. View Institutional Ownership Trends for Dova Pharmaceuticals.

DOVA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, State Street Corp and Barclays PLC. Company insiders that have sold Dova Pharmaceuticals company stock in the last year include David Zaccardelli, Jason Hoitt, Kevin Laliberte, Lee F Md Phd Allen, Mark W Hahn and Roger Jeffs. View Insider Buying and Selling for Dova Pharmaceuticals.

DOVA stock was bought by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, Gabelli Funds LLC, GABELLI & Co INVESTMENT ADVISERS INC., Virtu Financial LLC, Tower Research Capital LLC TRC and Meeder Asset Management Inc.. Company insiders that have bought Dova Pharmaceuticals stock in the last two years include Alex Sapir, David Zaccardelli, Life Sciences Maste Perceptive, Paul B Manning and Steven M Goldman. View Insider Buying and Selling for Dova Pharmaceuticals.

Shares of DOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DOVA stock can currently be purchased for approximately $28.04.

Dova Pharmaceuticals has a market capitalization of $807.55 million and generates $10.35 million in revenue each year. The company earns $-72,280,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. Dova Pharmaceuticals employs 115 workers across the globe.View Additional Information About Dova Pharmaceuticals.

The official website for Dova Pharmaceuticals is http://www.dova.com/.

Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected]